Jaguar Health receives AAVSB RACE approval for foal CENovember 13, 2017Jaguar Health Inc., a manufacturer of gastrointestinal products for both human prescription use and animals, announced today that the American Association of Veterinary State Boards (AAVSB) Registry of Approved Continuing Education (RACE) committee has reviewed and approved Jaguar's "Diarrhea in Foals" continuing education (CE) program as meeting the standards adopted by the AAVSB. The company's "Diarrhea in Foals" program has been approved by the AAVSB RACE committee to offer a total of 1.50 CE credits to each participating veterinarian or veterinary technician. The program may be repeated by Jaguar within the two-year program approval period at different locations and/or on different dates, with advance notice to AAVSB. "Participation in CE programs helps veterinarians and veterinary technicians remain apprised of current and cutting-edge veterinary care and helping veterinary professionals expand their clinical knowledge and learn about new technology helps them take better care of their patients," said Siobhan McAuliffe, MVB, DACVIM. Dr. McAuliffe served as the primary investigator for clinical studies conducted in 2015 for Neonorm™ Foal, Jaguar's plant-based antidiarrheal product for newborn horses.
SPONSORED CONTENTOne dose protects for 12 months.One ProHeart® 12 (moxidectin) injection puts compliance in your control. + Get started
